TRIM28 and HIV infectious disease: Recent research suggests that TRIM28 (also known as KAP1) acts as a SUMO E3 ligase to SUMOylate cyclin‐dependent kinase 9 (CDK9) with SUMO4 at Lys 44, Lys56, and 68 residues, which prevents P‐TEFb assembly by directly blocking the interaction between CDK9 and Cyclin T1 (CycT1), and consequently inhibits viral transcription, contributing to HIV‐1 latency.[171] Hence, targeting TRIM28 and its SUMOylation pathway could provide a new direction for developing efficient latency‐reversing agents (LRAs) for treating HIV infection.